Clinical Trial Update: Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating IL-22 IgG2-Fc (F-652) for acute graft-versus-host disease (aGVHD) shows results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• IL-22 IgG2-Fc (F-652) (IL-22 IgG2-Fc)

Snippet

Sponsor: EVIVE Biotechnology | Conditions: Acute Graft vs Host Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-07-22